Drug: Lyrica
Company: Pfizer
Total spend Q1, 2012: $25.1 million
Total spend Q1, 2011: $30.8 million
Watch the TV commercial here >>

While Pfizer is remaking itself in a world without Lipitor exclusivity, it will at least be able to carry forward with protection another 5 years on its super blockbuster drug Lyrica. A federal judge in July upheld its patents for Lyrica, the pain drug and epilepsy treatment. Released in 2004, the drug first topped the $1 billion sales milestone in 2008 and its sales have just kept growing. Last year, Lyrica generated $3.7 billion in revenue. Federal authorities did say that some of that success was attributable to misbehavior. Lyrica was one of the drugs included in Pfizer's $2.3 billion marketing settlement in 2009. But that is past and the drug keeps generating big sales, including $458 million in the first quarter, says, which translates as a 6% jump.


Suggested Articles

AstraZeneca’s Farxiga is chasing an OK to treat heart failure regardless of a diabetes diagnosis. But in the meantime, it's scored a smaller nod.

Combined with Avastin, Roche's IO med beat Bayer's standard-of-care Nexavar at stalling liver cancer progression—and helped patients live longer, too.

A high-profile opioid trial was set to start today in Ohio, but now four companies have inked settlements to avoid trial.